Rekrutteringsfirma

Principal/ Senior Analytical Development Scientist

Denne stilling er desværre ikke længere ledig.
Se alle ledige stillinger

Gå tilbage til ledige stillinger

Principal/ Senior Analytical Development Scientist

Pioneer the development of a new class of drugs halting disease progression and restoring function.

https://uhc.dk/wp-content/uploads/2023/10/Video-teaser-Draft-V1.mp4

As Principal/ Senior Analytical Development Scientist at Vicore Pharma, you will be the project lead for analytical method development for Vicore’s lead candidate drugs.

Your main responsibilities include:

  • Developing, validating, and implementing product-specific analytical methods
  • Leading projects with analytical teams
  • Directing the outlining of agreements for analytical tasks
  • Managing execution of the analytical control strategies and the regulatory documentation for the CMC part of INDs/IMPDs, and eventually for the registration file

Your qualifications include at least five to seven years of experience in the pharmaceutical and/or biotechnology industry, where you have been actively working with CMC and analytical development, including small molecules. Additionally, you have contributed to regulatory documents and submissions, as well as involved in the clinical development of investigational new drugs.

You are a person who has a positive attitude and are open to collaborating and communicating with colleagues across different departments. Furthermore, you enjoy being challenged and can work with multiple tasks. As a principal /senior scientist, you find it natural to drive the fundamentals of the process of developing new medicine.

Vicore Pharma is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs, angiotensin II type 2 receptor agonists (ATRAG) for severe diseases.
Vicore has a unique expertise within the ATRAG biology and a holistic approach in diseases where the angiotensin II type 2 receptor has a central role in stopping and reversing disease pathology. Vicore’s pipeline has several assets with long patent life for a variety of diseases. Our lead indication is idiopathic pulmonary fibrosis, and our most advanced candidate drug, C21, is currently completing a phase 2a clinical trial and preparing for the next phase.

Vicore is a lean and agile organization with highly experienced professionals who cover the entire spectrum from early asset development through to commercialization and patient access. Vicore’s success hinges on the capacity to attract and retain talented individuals who are deeply committed, adaptable to change, and thrive in a dynamic environment with ambitious goals. All employees are equally important to turn the Vicore ambition into reality. Through valuing trust, integrity, and an open, friendly, and informal atmosphere, you can expect great opportunities for impact and growth.

Travelling: Approx. 10-20 days per year.

Domicile: Commuting distance from the Vicore office in Hørsholm, Copenhagen.

For more details about the job or the company, please contact Director Life Science Gert Andersen, Unique Human Capital, on M: +45 42 95 08 83, [email protected].
All applications must be in English and are treated confidentially.


Information og data

Denne ledige stilling har jobtypen "Forsker", og befinder sig i kategorien "Sundhed og forskning".

Jobbet er oprettet på vores service den 19.10.2023, men kan have været deaktiveret og genaktiveret igen.

Dagligt opdateret: Dette job opdateres dagligt ud fra jobudbyderens hjemmeside via vores søgemaskineteknologi og er aktivt lige nu.
  • Forsker

Statistik over udbudte jobs som forskere

Herunder ser du udviklingen i udbudte forsker over tid. Bemærk at jobs der ikke har en bestemt geografi ikke er medtaget i tabellen. I den første kolonne ser du datoen. I den næste kolonne ser du det samlede antal forskere.

Se flere statistikker her:
Statistik over udbudte forskere over tid

Dato Alle jobs som forskere
24. december 2024 383
23. december 2024 407
22. december 2024 414
21. december 2024 425
20. december 2024 431
19. december 2024 434
18. december 2024 407
17. december 2024 406
16. december 2024 400
15. december 2024 427
14. december 2024 397
13. december 2024 317
12. december 2024 323
11. december 2024 394
10. december 2024 403
9. december 2024 393
8. december 2024 395
7. december 2024 395
6. december 2024 409
5. december 2024 407
4. december 2024 397
3. december 2024 395
2. december 2024 406
1. december 2024 420
30. november 2024 419
29. november 2024 422
28. november 2024 438
27. november 2024 419
26. november 2024 410
25. november 2024 411
24. november 2024 407